Literature DB >> 16530101

Manufacture and acoustical characterisation of a high-frequency contrast agent for targeting applications.

C M Moran1, J A Ross, C Cunningham, M Butler, T Anderson, D Newby, K A A Fox, W N McDicken.   

Abstract

The aim of this study was to develop and acoustically to optimise an ultrasonic contrast agent for research imaging applications at 40 MHz. A range of liposomal dispersions were manufactured and the mean backscatter power was measured using a Boston Scientific ClearView Ultra intravascular scanner with a 40 MHz, 2.5 Fr Atlantis SR Plus catheter. The scanner had been modified to allow access to the unprocessed ultrasound data, which were digitised, and the mean backscatter power was calculated over a region-of-interest centred at 2 mm from the transducer. Mean backscatter power was normalised to the data collected from a water-air interface. The effects of sonication and rapid shaking on six liposomal samples were also studied and this indicated that both techniques significantly reduced the size of the liposomes within the dispersions. Maximum mean backscatter power was measured for sonicated liposomal dispersions with 60% by weight of phosphatidylethanolamine. Moreover, this dispersion had greater mean backscatter power than sheep blood at 40 MHz.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16530101     DOI: 10.1016/j.ultrasmedbio.2005.11.008

Source DB:  PubMed          Journal:  Ultrasound Med Biol        ISSN: 0301-5629            Impact factor:   2.998


  2 in total

1.  Evaluation of methods for sizing and counting of ultrasound contrast agents.

Authors:  Charles A Sennoga; James S M Yeh; Julia Alter; Eleanor Stride; Petros Nihoyannopoulos; John M Seddon; Dorian O Haskard; Joseph V Hajnal; Meng-Xing Tang; Robert J Eckersley
Journal:  Ultrasound Med Biol       Date:  2012-03-06       Impact factor: 2.998

2.  In vivo performance of a liposomal vascular contrast agent for CT and MR-based image guidance applications.

Authors:  Jinzi Zheng; Jubo Liu; Mike Dunne; David A Jaffray; Christine Allen
Journal:  Pharm Res       Date:  2007-03-21       Impact factor: 4.580

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.